Evoke Pharma Reports 47% Increase in Net Product Sales Despite Ongoing Losses in Q2 2025

Evoke Pharma, Inc. reported its financial results for the second quarter of 2025, revealing a significant increase in net product sales and ongoing operational challenges. For the three months ended June 30, 2025, the company generated net product sales of approximately $3.75 million, a 47% increase from $2.55 million in the same period last year. For the first half of 2025, net product sales reached $6.83 million, up 59% from $4.29 million in the prior year. Despite this growth, Evoke reported a net loss of $1.57 million for the quarter, compared to a loss of $1.27 million in Q2 2024, and a total net loss of $2.88 million for the first half of 2025, slightly higher than the $2.85 million loss recorded in the same period last year.

The company's operating expenses also saw a notable increase, with total operating expenses for the second quarter rising to $5.31 million, up from $3.77 million in Q2 2024. This increase was primarily driven by higher selling, general, and administrative expenses, which rose to $5.13 million from $3.73 million, largely due to increased marketing efforts and profit-sharing costs associated with its commercial partner, Eversana. Research and development expenses also increased significantly, reflecting ongoing product development activities.

Evoke's balance sheet as of June 30, 2025, showed total assets of approximately $16.06 million, down from $17.52 million at the end of 2024. The company reported cash and cash equivalents of $12.06 million, a decrease from $13.60 million at the end of the previous fiscal year. Current liabilities increased to $11.62 million, up from $10.38 million, primarily due to higher accounts payable and accrued expenses. The company's stockholders' equity decreased to $4.37 million from $7.04 million, reflecting ongoing losses and operational expenditures.

In terms of operational metrics, Evoke reported a 9.3% increase in new inbound prescriptions for its product, Gimoti, during the second quarter, with approximately 1,960 new prescriptions processed. The company continues to expand its pharmacy network, which has improved insurance coverage for patients and increased prescription fill rates. However, the company faces substantial risks, including the potential termination of its agreement with Eversana, which could significantly impact its operations and financial stability.

Looking ahead, Evoke anticipates continued losses as it invests in commercialization activities and product development. The company has indicated that it may need to raise additional funds to support its operations, particularly if it cannot secure sufficient revenue from Gimoti sales. Management has expressed substantial doubt about the company's ability to continue as a going concern over the next year, emphasizing the need for strategic financing and operational adjustments to ensure long-term viability.